The UK's cell therapy industry now has a database of all ongoing clinical trials in the country with the aim of expanding research partnerships and pushing more early-stage trials to later stages.
Covance says its agreement with the Royal Liverpool and Broadgreen University Hospitals NHS Trust will improve drug development and bring drugs to market sooner.
The UK government’s health committee is calling for all clinical trial information to be in the public domain but industry push back is expected, experts say.
EU pharmaceutical and active substance manufacturers should determine the threshold for cross-contamination when multiple drugs are produced in shared facilities.
The end of the world is likely to have a negative impact on clinical trials according to research published in the journal of the Canadian Medical Association.
Collaborations and expansions dominate Outsourcing-pharma.com’s roundup of developments in the CRO space, with news from Cenduit, Perceptive Informatics, INC Reseach and Spaulding Clinical Research.
Researchers say cluster randomized trials (CRTs) present "distinct ethical challenges" and have created 15 "guidelines" to help researchers and ethics committees address them.
Swedish CRO Trial Form Support International (TFS) has bought Italian counterpart Dimensione Ricerca to strengthen its presence in Southern Europe and key therapeutic areas like oncology.
The group whose comments on sponsor oversight drew criticism from ACRO says the industry group's preferred ‘trust and verify’ model only works if verification efforts are robust.
The US FDA wants IRBs to remember it is their responsibility to check investigator qualifications, make sure sites are up to code and say if an IND is necessary for the proposed trial.
Outsourcing-pharma.com readers want the acronym CRO to stand for 'contract research organisation' according to the results of a snap poll we ran yesterday.
Outsourcing-pharma.com witnessed a fascinating debate on the definition of ‘CRO’ yesterday with terms like 'collaboration' and 'release' being suggested as potential alternatives.
More analysis suggests that collecting data for non-core endpoints costs individual sponsors millions per clinical trial and the industry billions each year.
Discovery of the genetic basis for the placebo effect in IBS patients has wider implications for protocol design and trials of personalised medicines say researchers.
